Developers work with the NHS, the medicines regulator and the UK health technology assessment bodies from the early stages of clinical development, as part of the Innovative Licensing and Access Pathway.
UK MHRA · October 14, 2025
The new Innovative Licensing and Access Pathway welcomes first investigational products
The UK MHRA announces the first investigational products enrolled in the Innovative Licensing and Access Pathway, enabling early-stage developer engagement with regulators and HTA bodies.
Published by UK MHRA. HealthSignal links to the original document; the summary above is extracted from the source text.